Immucell Corp.

NASDAQ:ICCC   10:55:07 AM EDT
8.78
-0.09 (-1.01%)
Products

Immucell Receives Technical Section Incomplete Letter From FDA Pertaining To Re-Tain

Published: 07/28/2022 00:13 GMT
Immucell Corp. (ICCC) - Immucell Receives Technical Section Incomplete Letter From FDA Pertaining to Re-tain.
Principal Issue Remaining is a Successful Pre-approval Re-inspection of Its Manufacturing Facility.completing Preparations for Such and Intends to Notify the FDA of Its Readiness for the Re-inspection During the Third Quarter.company Intends to Make a Third Submission of Its Cmc Technical Section in Response to These Questions During Q3.
Finalizing the Remaining Minor Technical Sections and Preparing to File the Administrative Nada While Planning for Market Launch.